Icure Pharmaceutical Incorporation Asset Resilience Ratio

Latest as of March 2025: 5.45%

Icure Pharmaceutical Incorporation asset resilience ratio. Icure Pharmaceutical Incorporation (175250) has an Asset Resilience Ratio of 5.45% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 175250 defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Liquid Assets

₩6.75 Billion

≈ $4.57 Million USD Cash + Short-term Investments

Total Assets

₩123.73 Billion

≈ $83.85 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio of Icure Pharmaceutical Incorporation (2016–2024)

Asset resilience ratio of Icure Pharmaceutical Incorporation from 2016 to 2024. This chart shows how Icure Pharmaceutical Incorporation's Asset Resilience Ratio has changed over time. Read 175250 current and long-term liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Icure Pharmaceutical Incorporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Icure Pharmaceutical Incorporation balance sheet assets.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩4.49 Billion	3.63%
Short-term Investments	₩2.25 Billion	1.82%
Total Liquid Assets	₩6.75 Billion	5.45%

Asset Resilience Insights

Limited Liquidity: Icure Pharmaceutical Incorporation maintains only 5.45% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Icure Pharmaceutical Incorporation Industry Peers by Asset Resilience Ratio

Compare Icure Pharmaceutical Incorporation's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Jiangsu Nhwa Pharmaceutical Co Ltd SHE:002262	Drug Manufacturers - Specialty & Generic	26.45%
Tibet Rhodiola Pharmaceutical Holding Co SHG:600211	Drug Manufacturers - Specialty & Generic	11.84%
Shanghai Yizhong Pharmaceutical Co Ltd SHG:688091	Drug Manufacturers - Specialty & Generic	26.36%
Renhe Pharmacy Co Ltd SHE:000650	Drug Manufacturers - Specialty & Generic	37.54%
Bide Pharmatech Co. Ltd. A SHG:688073	Drug Manufacturers - Specialty & Generic	9.46%
Jianmin Pharmaceutical Group Co Ltd SHG:600976	Drug Manufacturers - Specialty & Generic	20.61%
Qianjiang Yongan Pharmaceutical Co Ltd SHE:002365	Drug Manufacturers - Specialty & Generic	30.38%
Shenzhen Neptunus Bioengineering Co Ltd SHE:000078	Drug Manufacturers - Specialty & Generic	0.42%

Icure Pharmaceutical Incorporation Asset Resilience Ratio by Year (2016–2024)

Icure Pharmaceutical Incorporation asset resilience ratio by year from 2016 to 2024. The table below shows the annual Asset Resilience Ratio data for Icure Pharmaceutical Incorporation.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	16.88%	₩22.44 Billion ≈ $15.20 Million	₩132.88 Billion ≈ $90.05 Million	+11.73pp
2023-12-31	5.15%	₩8.56 Billion ≈ $5.80 Million	₩166.14 Billion ≈ $112.59 Million	-18.85pp
2022-12-31	24.00%	₩53.79 Billion ≈ $36.45 Million	₩224.12 Billion ≈ $151.88 Million	+12.67pp
2021-12-31	11.33%	₩24.42 Billion ≈ $16.55 Million	₩215.45 Billion ≈ $146.01 Million	+4.30pp
2020-12-31	7.03%	₩13.72 Billion ≈ $9.30 Million	₩195.15 Billion ≈ $132.25 Million	-1.77pp
2019-12-31	8.80%	₩18.99 Billion ≈ $12.87 Million	₩215.80 Billion ≈ $146.24 Million	-19.97pp
2018-12-31	28.77%	₩34.81 Billion ≈ $23.59 Million	₩121.00 Billion ≈ $82.00 Million	+11.05pp
2017-12-31	17.72%	₩9.55 Billion ≈ $6.47 Million	₩53.90 Billion ≈ $36.53 Million	+14.35pp
2016-12-31	3.37%	₩1.06 Billion ≈ $720.17K	₩31.53 Billion ≈ $21.36 Million	--

pp = percentage points

About Icure Pharmaceutical Incorporation

KQ:175250 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$54.96 Million

₩81.09 Billion KRW

Market Cap Rank

#21329 Global

#1258 in Korea

Share Price

₩2170.00

Change (1 day)

+0.00%

52-Week Range

₩2170.00 - ₩2170.00

All Time High

₩23730.97